Logo Innoviva, Inc.

Innoviva, Inc. (INVA) stock: analyst price target and their real reliability

Live quote · data updated Aug 28, 2026
Innoviva, Inc. · Health Care · ref. ETF XLV · 37 calls · price $20.96
🏆JPI 2026 portfoliosSee tracking →
What the company does: Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally.

📈 Innoviva, Inc. (INVA) stock price

$20.96+4.6% over range
Aug 28, 25low $16.67 · high $24.24Aug 27, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Buy
100% recommend buying · 3 analysts
📊 JPI status : Innoviva, Inc. is currently in 🎯 JPI Fair n°2 · ⚡ JPI Risk + n°12.

🎯 INVA price target & analyst consensusprice $20.96

The price target · all analysts combined (3 targets)
Highest target · 1 firm of 3$46+119.5%
Median target · of 3 targets$42+100.4%
Lowest target · 1 firm of 3$34+62.2%
Current price$20.96
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: HC Wainwright & Co.61% of its targets hit on this sector (321 calls tested). It aims for $46 (+120 %), call made on June 2, 2026, maturing on June 2, 2027 (87 d ago).

The 1 reliable analyst $46+120 %
The 2 other firms $38+81 %
How to read it: the 1 reliable firms are not filtered by optimism — 1 aim above the price, 0 below, hence their $46 median. “The 2 others” are the firms that don't pass our reliability filter on this sector.
The consensus · 3 ratings (last 6 months)
Strong Buy00%
Buy3100%
Hold00%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Innoviva, Inc.? The JPI assistant answers using our backtest data.

🔎 Detailed analyses

✅ Historical analyst reliability on INVA

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm % right i Gain vs sector i Calls i
HC Wainwright & Co.  100% +8.3% 2
EF Hutton 75% +13.6% 4
Cantor Fitzgerald  60% +15.1% 5
Morgan Stanley  56% -5.4% 9

📊 What $1,000 invested in Innoviva, Inc. would be worth › open the full page

In short — $1,000 invested in Innoviva, Inc. 10 years ago would be worth $2,063 today, i.e. +8%/yr on average. Best year: 2021 (+39%), worst: 2022 (-23%). Price performance, excluding dividends.

If I'd invested $1,000 in Innoviva, Inc.

InvestmentWorth todayGain
1 years ago$1,253+25%
3 years ago$1,641+64%
5 years ago$1,755+75%
→ See Innoviva, Inc.'s full return history + gain calculator

Return by year (Innoviva, Inc.)

YearReturn$1,000 invested at year start
2026 (YTD)+9%$1,088 (+9%)
2025+15%$1,253 (+25%)
2024+8%$1,355 (+36%)
→ See Innoviva, Inc.'s full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Innoviva, Inc.

Loading news…

📋 All analyst calls on INVA

▲ Overweight · 🎯$34
Price at call : $20.51 — upside +66%
Today : $20.96 — upside +62%
🎯 on INVA : 60% (5 calls matureds) · 📊 on Health : 50.6% · +13.8% (166 calls)
in progress (365j)
matures : Aug 7, 27
BTIG 
Jun 22, 26
▲ Buy · 🎯$42
Price at call : $23.55 — upside +78%
Today : $20.96 — upside +100%
🎯 on INVA : no call matured yet · 📊 on Health : 46.2% · +19.8% (65 calls)
in progress (365j)
matures : Jun 22, 27
▲ Buy · 🎯$46
Price at call : $21.51 — upside +114%
Today : $20.96 — upside +119%
🎯 on INVA : 100% (2 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
in progress (365j)
matures : Jun 1, 27
BTIG 
May 26, 26
▲ Buy · 🎯$42
Price at call : $22.68 — upside +85%
Today : $20.96 — upside +100%
🎯 on INVA : no call matured yet · 📊 on Health : 46.2% · +19.8% (65 calls)
in progress (365j)
matures : May 26, 27
BTIG 
May 7, 26
▲ Buy · 🎯$42
Price at call : $22.8 — upside +84%
Today : $20.96 — upside +100%
🎯 on INVA : no call matured yet · 📊 on Health : 46.2% · +19.8% (65 calls)
in progress (365j)
matures : May 7, 27
BTIG 
Feb 26, 26
▲ Buy · 🎯$35
Price at call : $23.54 — upside +49%
Today : $20.96 — upside +67%
🎯 on INVA : no call matured yet · 📊 on Health : 46.2% · +19.8% (65 calls)
in progress (365j)
matures : Feb 26, 27
BTIG 
Feb 17, 26
▲ Buy · 🎯$35
Price at call : $23.85 — upside +47%
Today : $20.96 — upside +67%
🎯 on INVA : no call matured yet · 📊 on Health : 46.2% · +19.8% (65 calls)
in progress (365j)
matures : Feb 17, 27
▲ Buy · 🎯$46
Price at call : $19.92 — upside +131%
Today : $20.96 — upside +119%
🎯 on INVA : 100% (2 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
in progress (365j)
matures : Dec 16, 26
See the other 29 calls, newest to oldest
▲ Overweight · 🎯$31
Price at call : $20.86 — upside +49%
Today : $20.96 — upside +48%
🎯 on INVA : 60% (5 calls matureds) · 📊 on Health : 50.6% · +13.8% (166 calls)
in progress (365j)
matures : Nov 6, 26
Goldman Sachs 
Sep 30, 25
▼ Sell · 🎯$17
Price at call : $18.25 — upside -7%
Today : $20.96 — upside -19%
🎯 on INVA : no call matured yet · 📊 on Health : 51% · +5.1% (102 calls)
in progress (365j)
matures : Sep 30, 26
Oppenheimer 
Aug 11, 25
▲ Outperform · 🎯$35
Price at call : $19.65 — upside +78%
Today : $20.96 — upside +67%
Expected +78% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on INVA : 100% (1 call matured) · 📊 on Health : 47.3% · +6.3% (93 calls)
+5.6%
stock +6% · XLV +29%
matured Aug 11, 26
▲ Buy · 🎯$45
Price at call : $19.65 — upside +129%
Today : $20.96 — upside +115%
Expected +129% · Actual +6% · Reason (≥ +15%) : ✗ No
🎯 on INVA : 100% (2 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
+5.6%
stock +6% · XLV +29%
matured Aug 11, 26
▲ Buy · 🎯$40
Price at call : $19.58 — upside +104%
Today : $20.96 — upside +91%
Expected +104% · Actual +11% · Reason (≥ +15%) : ✗ No
🎯 on INVA : 100% (2 calls matureds) · 📊 on Health : 57.9% · +25.9% (321 calls)
+11.0%
stock +11% · XLV +17%
matured Jul 14, 26
▲ Overweight · 🎯$26
Price at call : $18.77 — upside +39%
Today : $20.96 — upside +24%
Expected +39% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on INVA : 60% (5 calls matureds) · 📊 on Health : 50.6% · +13.8% (166 calls)
+18.3%
stock +18% · XLV +19%
matured Jul 11, 26
Scotiabank 
Mar 7, 25
▲ Sector Outperform · 🎯$55
Price at call : $17.48 — upside +215%
Today : $20.96 — upside +162%
Expected +215% · Actual +28% · Reason (≥ +15%) : ✓ Yes
🎯 on INVA : 100% (1 call matured) · 📊 on Health : 80% · +13.8% (5 calls)
+27.7%
stock +28% · XLV +4%
matured Mar 7, 26
▲ Overweight
Actual -3% · Reason (≥ +15%) : ✗ No
🎯 on INVA : 60% (5 calls matureds) · 📊 on Health : 50.6% · +13.8% (166 calls)
-2.6%
stock -3% · XLV -12%
matured Aug 1, 25
▲ Overweight
Actual -4% · Reason (≥ +15%) : ✗ No
🎯 on INVA : 60% (5 calls matureds) · 📊 on Health : 50.6% · +13.8% (166 calls)
-3.6%
stock -4% · XLV -13%
matured Jul 30, 25
▲ Overweight
Actual +31% · Reason (≥ +15%) : ✓ Yes
🎯 on INVA : 60% (5 calls matureds) · 📊 on Health : 50.6% · +13.8% (166 calls)
+30.9%
stock +31% · XLV -10%
matured Jun 20, 25
▲ Overweight
Actual +32% · Reason (≥ +15%) : ✓ Yes
🎯 on INVA : 60% (5 calls matureds) · 📊 on Health : 50.6% · +13.8% (166 calls)
+32.3%
stock +32% · XLV -9%
matured Jun 18, 25
EF Hutton
May 10, 23
▲ Buy · 🎯$22.5
Price at call : $12.2 — upside +84%
Today : $20.96 — upside +7%
Expected +84% · Actual +25% · Reason (≥ +15%) : ✓ Yes
🎯 on INVA : 75% (4 calls matureds) · 📊 unranked overall
+25.3%
stock +25% · XLV +8%
matured May 9, 24
EF Hutton
Apr 20, 23
▲ Buy · 🎯$22.5
Price at call : $11.84 — upside +90%
Today : $20.96 — upside +7%
Expected +90% · Actual +26% · Reason (≥ +15%) : ✓ Yes
🎯 on INVA : 75% (4 calls matureds) · 📊 unranked overall
+26.3%
stock +26% · XLV +4%
matured Apr 19, 24
Goldman Sachs 
Mar 3, 23
■ Neutral neutral · not a buy · 🎯$13
Price at call : $11.02 — gap to target +18%
Today : $20.96 — gap to target -38%
🎯 on INVA : no call matured yet · 📊 on Health : 51% · +5.1% (102 calls)
in progress (365j)
matures : Mar 2, 24
▼ Underweight · 🎯$10
Price at call : $11.02 — upside -9%
Today : $20.96 — upside -52%
Expected -9% · Actual +38% · Reason (≤ −15%) : ✗ No
🎯 on INVA : 56% (9 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
-38.5%
stock +38% · XLV +13%
matured Mar 2, 24
EF Hutton
Mar 3, 23
▲ Buy · 🎯$22.5
Price at call : $10.99 — upside +105%
Today : $20.96 — upside +7%
Expected +105% · Actual +39% · Reason (≥ +15%) : ✓ Yes
🎯 on INVA : 75% (4 calls matureds) · 📊 unranked overall
+38.9%
stock +39% · XLV +13%
matured Mar 2, 24
Morgan Stanley 
Jan 24, 23
▼ Underweight · 🎯$13
Price at call : $12.43 — upside +5%
Today : $20.96 — upside -38%
Expected +5% · Actual +31% · Reason (≤ −15%) : ✗ No
🎯 on INVA : 56% (9 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
-31.5%
stock +31% · XLV +4%
matured Jan 24, 24
Morgan Stanley 
Oct 13, 22
▼ Underweight · 🎯$14
Price at call : $13.37 — upside +5%
Today : $20.96 — upside -33%
Expected +5% · Actual -0% · Reason (≤ −15%) : ✗ No
🎯 on INVA : 56% (9 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+0.4%
stock -0% · XLV +4%
matured Oct 13, 23
▼ Underweight · 🎯$13
Price at call : $14.37 — upside -10%
Today : $20.96 — upside -38%
Expected -10% · Actual -5% · Reason (≤ −15%) : ✗ No
🎯 on INVA : 56% (9 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+4.9%
stock -5% · XLV +3%
matured Aug 8, 23
Goldman Sachs 
Jul 20, 22
■ Neutral neutral · not a buy · 🎯$16
Price at call : $14.41 — gap to target +11%
Today : $20.96 — gap to target -24%
🎯 on INVA : no call matured yet · 📊 on Health : 51% · +5.1% (102 calls)
in progress (365j)
matures : Jul 20, 23
Morgan Stanley 
Jul 15, 22
▼ Underweight · 🎯$12
Price at call : $14.51 — upside -17%
Today : $20.96 — upside -43%
Expected -17% · Actual -14% · Reason (≤ −15%) : ✗ No
🎯 on INVA : 56% (9 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+14.1%
stock -14% · XLV +3%
matured Jul 15, 23
Morgan Stanley 
Apr 12, 22
▼ Underweight · 🎯$13
Price at call : $19.3 — upside -33%
Today : $20.96 — upside -38%
Expected -33% · Actual -37% · Reason (≤ −15%) : ✓ Yes
🎯 on INVA : 56% (9 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+36.8%
stock -37% · XLV -3%
matured Apr 12, 23
Morgan Stanley 
Feb 23, 22
▼ Underweight · 🎯$12
Price at call : $19.17 — upside -37%
Today : $20.96 — upside -43%
Expected -37% · Actual -37% · Reason (≤ −15%) : ✓ Yes
🎯 on INVA : 56% (9 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
+36.6%
stock -37% · XLV +3%
matured Feb 23, 23
EF Hutton
Feb 11, 22
▲ Buy · 🎯$28
Price at call : $19.25 — upside +45%
Today : $20.96 — upside +34%
Expected +45% · Actual -36% · Reason (≥ +15%) : ✗ No
🎯 on INVA : 75% (4 calls matureds) · 📊 unranked overall
-36.0%
stock -36% · XLV +3%
matured Feb 11, 23
Morgan Stanley 
Nov 11, 20
▼ Underweight · 🎯$10
Price at call : $10.83 — upside -8%
Today : $20.96 — upside -52%
Expected -8% · Actual +65% · Reason (≤ −15%) : ✗ No
🎯 on INVA : 56% (9 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
-64.5%
stock +65% · XLV +20%
matured Nov 11, 21
Stifel 
Apr 27, 18
■ Hold neutral · not a buy · 🎯$16
Price at call : $14.23 — gap to target +12%
Today : $20.96 — gap to target -24%
🎯 on INVA : no call matured yet · 📊 on Health : 44.8% · +6.7% (96 calls)
in progress (365j)
matures : Apr 27, 19
Deutsche Bank 
Nov 20, 17
■ Hold neutral · not a buy · 🎯$13
Price at call : $13.17 — gap to target -1%
Today : $20.96 — gap to target -38%
🎯 on INVA : no call matured yet · 📊 on Health : 32.7% · -7.6% (55 calls)
in progress (365j)
matures : Nov 20, 18
▼ Underweight · 🎯$8
Price at call : $14.32 — upside -44%
Today : $20.96 — upside -62%
Expected -44% · Actual +7% · Reason (≤ −15%) : ✗ No
🎯 on INVA : 56% (9 calls matureds) · 📊 on Health : 55.5% · +4.6% (182 calls)
-7.3%
stock +7% · XLV +14%
matured Oct 6, 18
Cowen & Co.
Oct 31, 16
▲ Outperform
Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on INVA : 100% (1 call matured) · 📊 unranked overall
+18.8%
stock +19% · XLV +20%
matured Oct 31, 17

Frequently asked questions

Should I buy Innoviva, Inc. stock?

This isn't buy advice. For Innoviva, Inc., the analyst consensus is "Buy", with an average price target of $42.00 (+100% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (2 calls tracked on Innoviva, Inc.). We show the numbers — you decide.

Is it too late to buy Innoviva, Inc.? How high can it go?

The most bullish analyst target on Innoviva, Inc. is $46.00 (+119% above today's price); the average is $42.00. That's the upside they see. Check how reliable those analysts have actually been on Innoviva, Inc. on our site before trusting it.

Is Innoviva, Inc. still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 4 analysts have a real record on Innoviva, Inc., the best hitting 100% over 2 calls. Current consensus: "Buy". Make your call on data, not noise.

What has Innoviva, Inc.'s past performance been?

Historical returns and a "how much if I had invested" calculator: INVA performance & returns.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)